Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 404

Results For "RAT"

7948 News Found

Zydus receives final USFDA approval for Erythromycin Tablets
Drug Approval | September 03, 2023

Zydus receives final USFDA approval for Erythromycin Tablets

Erythromycin tablets is used to prevent and treat infections in many different parts of the body


BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData
News | September 03, 2023

BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData

BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials


Loop's health assurance model drives 200% YoY premium surge across 1000 companies
Healthcare | September 02, 2023

Loop's health assurance model drives 200% YoY premium surge across 1000 companies

Health Assurance is a unique healthcare model that combines health insurance with preventive healthcare with a focus on keeping people healthy while providing sick care for them when needed


India's digital startup ecosystem a catalyst for global healthcare transformation: Piyush Goyal
Digitisation | September 02, 2023

India's digital startup ecosystem a catalyst for global healthcare transformation: Piyush Goyal

Robots make it to the healthcare conference panel, reflecting the future potential of technology


USFDA delegation visits Amneal Pharmaceutical facility in Matoda
News | September 02, 2023

USFDA delegation visits Amneal Pharmaceutical facility in Matoda

Amneal’s site in Matoda is one of the company’s 12 pharmaceutical manufacturing facilities


Jupiter Life Line Hospitals’ IPO to open on Sept. 6
News | September 02, 2023

Jupiter Life Line Hospitals’ IPO to open on Sept. 6

Sets price band at ?695 to ?735 per Equity Share


Biocon acquires oral solid dosage manufacturing facility of Eywa Pharma for US$7.7 million
News | September 02, 2023

Biocon acquires oral solid dosage manufacturing facility of Eywa Pharma for US$7.7 million

The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year


USFDA approves BMS’ Reblozyl as first-line treatment of anemia in adults with Myelodysplastic Syndromes
Drug Approval | September 01, 2023

USFDA approves BMS’ Reblozyl as first-line treatment of anemia in adults with Myelodysplastic Syndromes

Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia


Sanofi, Meningitis Research Foundation and CoMO launch awareness initiative on meningitis
News | September 01, 2023

Sanofi, Meningitis Research Foundation and CoMO launch awareness initiative on meningitis

Meningitis still affects more than 2.5 million people globally each year